source
- Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlookNovartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
- Nine California biotech firms slash at least half of their workforces amid statewide cutsWorkforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…